Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announces that all items on the agenda of today's Annual General Meeting of Shareholders (AGM) have been approved by the Shareholders.
At the AGM, Dr. Sijmen de Vries, Chief Executive Officer of Pharming, presented the 2009 results and the outlook of the Company for 2010. This presentation can be found on the Pharming website. Main topics at the meeting were financing of the Company, the progress on the European Marketing Authorization Application (MAA) for Rhucin and the anticipated Day 210 EMA opinion on the MAA by end of June, followed by the adoption of the opinion and the granting of the Marketing Authorisation at Day 277 by the European Commission in FY10 Q3. Management confirmed its confidence on a positive outcome of the MAA process.
At the AGM, the majority of Shareholders voted in favour of the proposed items on the agenda. The agenda included the proposal to increase the annual remuneration of Pharming's CEO and the members of the Board of Supervisory Directors. Both the members of the Board of Supervisory Directors, as well as Pharming's CEO, voluntarily declined the proposed increases.
Mr. Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors, said: "Securing the Company's future and long-term value for our shareholders is our first priority. Achieving financial stability is vital in order for Pharming to reach its corporate goals. We highly appreciate management's efforts to improve the financial situation of the Company and the position of the Company as a whole."
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin(R) for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan(R) -- a product under development by Pharming's subsidiary DNage -- is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin- out of DNage was initiated. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.